EXTON, PA – Frontage Laboratories, Inc., has completed the renovation of a key clinical center in China to accommodate the growing need for early phase  oncology research studies.  Frontage, global contract research organization (CRO), began operations at the clinic earlier in 2011 and dedicated the Dec. 16 reopening with an early phase clinical research symposium.

Frontage VP Zeke Li, MD, far right, dedicates reopening

Based at Jilin University Hospital, which has a highly regarded oncology department, the Frontage center is redesigned to improve operational flexibility with a new intensive care unit enabling it to host a full range of cancer studies including treatment, prevention, screening, diagnostic and supportive care research.  A full time leading primary investigator manages the clinic with support for specialized studies from several sub-investigator oncologists who serve on the Jilin University Hospital staff.

The Frontage center offers clinical trial design, study recruitment and management, biostatistics services, and regulatory planning for FDA, EMEA, and China State Food and Drug Administration (SFDA) submissions with a concentration in Phase I and bioequivalence studies in oncology and other therapeutic areas.

Speakers from J&J, Roche and Novartis address Frontage Symposium

In connection with the reopening, Frontage held a symposium featuring leaders from the China clinical operations of several major pharmaceutical companies.  This group included Johnson & Johnson’s Head of Asia Pacific Global Clinical Operations, the Senior Director of Novartis Clinical Research in China, and the Director of Roche China Early Clinical Research.  Also speaking at the symposium were officials from Jilin University Hospital and the SFDA.

Covering topics such as early phase collaboration with contract research organizations, the speakers addressed an audience of 100 oncologists and clinical professionals from Jilin University, local regulators and representatives from several Chinese pharmaceutical companies including Novast Pharmaceuticals Ltd., a generic drug manufacturer.  Following the presentations, Frontage executives led a tour of the new clinical center for symposium attendees.

About Frontage

Frontage Laboratories, Inc. is a global contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services.  Frontage operates in the US and China, using one seamless GXP platform.  Frontage runs three Phase 1 Clinical units, a 72-bed Phase 1 Unit in Hackensack, NJ, a 120-bed Phase 1 Unit in Zhengzhou, Henan Province China, and a-80 bed Phase 1 Unit in Changchun, Jiling Province China.  Frontage has an AALAC certified preclinical animal facility in Pennsylvania, where it also maintains bioanalytical and CMC facilities. In Shanghai and Beijing, China, the company also operates bioanalytical and CMC facilities.  As a rapidly expanding CRO with ten years of success providing high-quality GXP services, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.

CONTACT:

Matt Harrington, Frontage Labs, Inc.
610.724.7301